Published in J Negat Results Biomed on July 18, 2015
Selection of a Relevant In Vitro Blood-Brain Barrier Model to Investigate Pro-Metastatic Features of Human Breast Cancer Cell Lines. PLoS One (2016) 0.78
An Investigation into the Immunomodulatory Activities of Sutherlandia frutescens in Healthy Mice. PLoS One (2016) 0.75
Does Concurrent Use of Some Botanicals Interfere with Treatment of Tuberculosis? Neuromolecular Med (2016) 0.75
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
The NLRP3 inflammasome: a sensor for metabolic danger? Science (2010) 4.33
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr J (2005) 1.99
Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods (2003) 1.74
HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol (1999) 1.63
Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol (2008) 1.54
Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood (2010) 1.44
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J (2007) 1.14
Anti-HIV activities of organic and aqueous extracts of Sutherlandia frutescens and Lobostemon trigonus. J Ethnopharmacol (2005) 1.08
Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology (2006) 1.05
Unexpected transcriptional induction of monocyte chemoattractant protein 1 by proteasome inhibition: involvement of the c-Jun N-terminal kinase-activator protein 1 pathway. J Immunol (2001) 1.03
Anticonvulsant property of Sutherlandia frutescens R. BR. (variety Incana E. MEY.) [Fabaceae] shoot aqueous extract. Brain Res Bull (2007) 1.02
Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology (2014) 0.99
The effect of Sutherlandia frutescens on steroidogenesis: confirming indigenous wisdom. Endocr Res (2004) 0.97
Sutherlandia frutescens ethanol extracts inhibit oxidative stress and inflammatory responses in neurons and microglial cells. PLoS One (2014) 0.94
The influence of Sutherlandia frutescens on adrenal steroidogenic cytochrome P450 enzymes. J Ethnopharmacol (2008) 0.93
HIV neuropathogenesis: a tight rope walk of innate immunity. J Neuroimmune Pharmacol (2010) 0.92
Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC. on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets. Cancer Lett (2005) 0.92
Use of the MTT assay in adult ventricular cardiomyocytes to assess viability: effects of adenosine and potassium on cellular survival. J Mol Cell Cardiol (1997) 0.89
Molecular mechanisms involved in HIV-1 Tat-mediated induction of IL-6 and IL-8 in astrocytes. J Neuroinflammation (2014) 0.88
Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats. Int J Pharm (2011) 0.87
The potential of Sutherlandia frutescens for herb-drug interaction. Drug Metab Dispos (2012) 0.83
Daily brief restraint stress alters signaling pathways and induces atrophy and apoptosis in rat skeletal muscle. Stress (2010) 0.82
Contusion injury with chronic in vivo polyphenol supplementation: leukocyte responses. Med Sci Sports Exerc (2014) 0.79
Central and peripheral effects of Sutherlandia frutescens on the response to acute psychological stress. Exp Biol Med (Maywood) (2013) 0.78
Effect of the African Traditional Medicine, Sutherlandia frutescens, on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir. Evid Based Complement Alternat Med (2013) 0.78